Our verdict is Benign. Variant got -20 ACMG points: 0P and 20B. BP4_StrongBP6_Very_StrongBS1BS2
The NM_001371596.2(MFSD8):c.66A>T(p.Glu22Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00164 in 1,606,132 control chromosomes in the GnomAD database, including 39 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★). Synonymous variant affecting the same amino acid position (i.e. E22E) has been classified as Likely benign.
MFSD8 (HGNC:28486): (major facilitator superfamily domain containing 8) This gene encodes a ubiquitous integral membrane protein that contains a transporter domain and a major facilitator superfamily (MFS) domain. Other members of the major facilitator superfamily transport small solutes through chemiosmotic ion gradients. The substrate transported by this protein is unknown. The protein likely localizes to lysosomal membranes. Mutations in this gene are correlated with a variant form of late infantile-onset neuronal ceroid lipofuscinoses (vLINCL). [provided by RefSeq, Oct 2008]
Computational evidence support a benign effect (MetaRNN=0.0062261224).
BP6
Variant 4-127957589-T-A is Benign according to our data. Variant chr4-127957589-T-A is described in ClinVar as [Likely_benign]. Clinvar id is 129611.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr4-127957589-T-A is described in Lovd as [Likely_benign]. Variant chr4-127957589-T-A is described in Lovd as [Benign].
BS1
Variant frequency is greater than expected in population afr. gnomad4 allele frequency = 0.00875 (1332/152278) while in subpopulation AFR AF= 0.03 (1247/41564). AF 95% confidence interval is 0.0286. There are 23 homozygotes in gnomad4. There are 627 alleles in male gnomad4 subpopulation. Median coverage is 32. This position pass quality control queck.
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center
-
- -
Benign, criteria provided, single submitter
clinical testing
GeneDx
Jun 05, 2012
This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease. -
Benign, criteria provided, single submitter
clinical testing
Genetic Services Laboratory, University of Chicago
Feb 08, 2016
- -
Neuronal ceroid lipofuscinosis 7 Benign:2
Benign, criteria provided, single submitter
clinical testing
Invitae
Feb 01, 2024
- -
Benign, criteria provided, single submitter
clinical testing
Illumina Laboratory Services, Illumina
Jan 12, 2018
This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score and internal cut-off values, a variant classified as benign is not then subjected to further curation. The score for this variant resulted in a classification of benign for this disease. -
Neuronal ceroid lipofuscinosis 7;C4015371:Macular dystrophy with central cone involvement Benign:1
Likely benign, criteria provided, single submitter
clinical testing
Fulgent Genetics, Fulgent Genetics
Dec 01, 2021
- -
Inborn genetic diseases Benign:1
Benign, criteria provided, single submitter
clinical testing
Ambry Genetics
Mar 18, 2016
This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Gain of glycosylation at S20 (P = 0.021);Gain of glycosylation at S20 (P = 0.021);Gain of glycosylation at S20 (P = 0.021);Gain of glycosylation at S20 (P = 0.021);Gain of glycosylation at S20 (P = 0.021);Gain of glycosylation at S20 (P = 0.021);Gain of glycosylation at S20 (P = 0.021);Gain of glycosylation at S20 (P = 0.021);Gain of glycosylation at S20 (P = 0.021);Gain of glycosylation at S20 (P = 0.021);Gain of glycosylation at S20 (P = 0.021);Gain of glycosylation at S20 (P = 0.021);Gain of glycosylation at S20 (P = 0.021);Gain of glycosylation at S20 (P = 0.021);Gain of glycosylation at S20 (P = 0.021);